SCHEMBL5690071

SCHEMBL5690071

CN(CCOc1ccccc1)[C@H]1CC[C@H](c2ccc(OCc3ccccc3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
MRGPRX4 Q96LA9 1/20 0.47
HRH3 Q9Y5N1 2/20 0.45
KCNH2 Q12809 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
LTA4H P09960 3/20 0.44
MCHR1 Q99705 1/20 0.43
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA7 P36544 1/20 0.41
CHRNA4 P43681 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5690074 1.00 KDM4E (0.49) KDM4EMRGPRX4HRH3KCNH2CYP3A4
SCHEMBL5689665 0.94 KDM4E (0.46) KDM4EMRGPRX4HRH3KCNH2CYP3A4
SCHEMBL5689670 0.94 KDM4E (0.46) KDM4EMRGPRX4HRH3KCNH2CYP3A4
SCHEMBL5690106 0.94 KDM4E (0.46) KDM4EMRGPRX4HRH3KCNH2CYP3A4
SCHEMBL5689857 0.93 KDM4E (0.45) KDM4EMRGPRX4HRH3KCNH2CYP3A4
SCHEMBL5689775 0.93 KDM4E (0.45) KDM4EMRGPRX4HRH3KCNH2CYP3A4
SCHEMBL5689361 0.92 MRGPRX4 (0.46) KDM4EMRGPRX4HRH3KCNH2CYP3A4
SCHEMBL5689359 0.92 MRGPRX4 (0.46) KDM4EMRGPRX4HRH3KCNH2CYP3A4
SCHEMBL5690583 0.89 KDM4E (0.44) KDM4EMRGPRX4HRH3KCNH2CYP3A4
SCHEMBL5690585 0.89 KDM4E (0.44) KDM4EMRGPRX4HRH3KCNH2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0982026-B1 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers HOFFMANN LA ROCHE (CH) 2006-05-17 EP disclosed
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 US disclosed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 EP disclosed